Rifaximin is a semi-synthetic antibiotic from the rifamycin class that acts locally in the gastrointestinal tract. It inhibits bacterial RNA polymerase, blocking RNA and protein synthesis and leading to bacterial cell death. Due to minimal systemic absorption, it achieves high intestinal concentrations with a favorable safety profile.
Recommended for:
Clinical trials have demonstrated rifaximin’s efficacy in traveler’s diarrhea and SIBO management. Large randomized controlled studies have shown significant reduction in hepatic encephalopathy recurrence rates. Its low systemic absorption contributes to reduced risk of systemic adverse effects.
Indicated for the treatment of gastrointestinal infections caused by susceptible bacteria. Used to reduce diarrhea symptoms, decrease intestinal bacterial load, and prevent complications in patients with chronic liver disease. Provides targeted local antibacterial action.
Administer orally with water. Dosage and duration of therapy should be determined by a healthcare professional based on the specific indication and patient condition. Adherence to the prescribed regimen is important for optimal effectiveness.
Contraindications
Side Effects
